Dexamethasone, Eltrombopag, Rituximab, and Romiplostim Combination

The provided search results do not contain specific information about a combination therapy using all four drugs: dexamethasone, eltrombopag, rituximab, and romiplostim, used together as a single, studied regimen. However, the individual drugs are known for their roles in treating immune thrombocytopenia (ITP) and have been studied in various three-drug combinations: * **Dexamethasone, Rituximab, and Romiplostim:** This combination has been studied as a "total therapy" approach for ITP, showing promising results with high response rates and acceptable safety profiles. * **Eltrombopag, Low-dose Rituximab, and Dexamethasone:** This combination has also been studied for ITP with positive outcomes. **Individual Drug Roles:** * **Dexamethasone:** A corticosteroid used in high doses as part of combination therapy for ITP. It acts as an immunosuppressant. * **Eltrombopag:** A thrombopoietin receptor agonist (TPO-RA) that stimulates platelet production by activating the thrombopoietin receptor (c-Mpl). It's used to treat thrombocytopenia in ITP. * **Rituximab:** A monoclonal antibody that targets B cells, which are involved in the autoimmune response in ITP. It aims to deplete these cells. * **Romiplostim:** Also a thrombopoietin receptor agonist (TPO-RA), similar to eltrombopag, it stimulates platelet production by activating the thrombopoietin receptor (c-Mpl). It's used for chronic immune thrombocytopenia when other treatments have failed.